Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features

Fumiaki Sato, Zhe Jin, Karsten Schulmann et al. · 2008

Read Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features by Fumiaki Sato, Zhe Jin, Karsten Schulmann et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001890.txt.

Introduction

Fumiaki Sato and colleagues built a scoring tool for a throat condition that can turn to cancer, in a 2008 PLOS ONE study. In Barrett esophagus, acid harm changes the lining of the food pipe, and a small share of cases move on to cancer. Watching all such patients closely is costly, and doctors did not agree on its worth.

The team sorted patients into three risk tiers using both health facts and chemical marks on DNA that can mute genes. A clear tier score helps doctors watch high-risk patients closely and spare low-risk ones needless tests. Work of this sort turns a vague worry into a plan with steps matched to risk.

Catalog record

CREATORFumiaki Sato, Zhe Jin, Karsten Schulmann et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001890

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features Authors: Fumiaki Sato, Zhe Jin, Karsten Schulmann, Jean Wang, Bruce D. Greenwald, Tetsuo Ito, Takatsugu Kan, James P. Hamilton, Jian Yang, Bogdan Paun, Stefan David, Alexandru Olaru, Yulan Cheng, Yuriko Mori, John M. Abraham, Harris G. Yfantis, Tsung-Teh Wu, Mary B. Fredericksen, Kenneth K. Wang, Marcia Canto, Yvonne Romero, Ziding Feng, Stephen J. Meltzer Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001890 ABSTRACT Barrett's esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic surveillance in Barrett's esophagus has been debated because of the low incidence of esophageal adenocarcinoma in Barrett's esophagus. Moreover, high inter-observer and sampling-dependent variation in the histologic staging of dysplasia make clinical risk assessment problematic. In this study, we developed a 3-tiered risk stratification strategy, based on systematically selected epigenetic and clinical parameters, to improve Barrett's esophagus surveillance efficiency. We defined high-grade dysplasia as endpoint of progression, and Barrett's esophagus progressor patients as Barrett's esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. We analyzed 4 epigenetic and 3 clinical parameters in 118 Barrett's esophagus tissues obtained from 35 progressor and 27 non-progressor Barrett's esophagus patients from Baltimore Veterans Affairs Maryland Health Care Systems and Mayo Clinic. Based on 2-year and 4-year prediction models using linear discriminant analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), Barrett's esophagus specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. This 3-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model. Progression-free survivals differed significantly among the 3 risk groups, with p = 0.0022 (HR vs. IR) and p<0.0001 (HR or IR vs. LR). Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy. This 3-tiered risk stratification strategy has the potential to exert a profound impact on Barrett's esophagus surveillance accuracy and efficiency. INTRODUCTION Barrett's esophagus (BE) is a premalignant condition in which normal squamous epithelium is replaced by a specialized metaplastic, small intestine-like, columnar lining [1] . BE predisposes patients to the future development of esophageal adenocarcinoma (EAC) [1] , [2] . The molecular mechanism of the Barrett's esophagus carcinogenic sequence (Barrett's esophagus mucosa, mild and severe dysplasia, to esophageal adenocarcinoma) has not been fully understood. It is believed that long-term inflammation due to gastro-esophageal reflux may cause genetic and epigenetic alterations in Barrett's esophagus, and that accumulation of these genetic and epigenetic alterations would lead the acquisition of malignant characteristics in the Barrett's cells, such as dysregulated cell proliferation, impaired apoptosis, and angiogenesis. As genetic alterations, loss of p16 gene expression (by deletion), the loss of p53 expression (by mutation and deletion), the increase in cyclin expression, and the losses of Rb, APC as well as various chromosomal loci in the Barrett's esophagus have been reported [3] . In addition, promoter hypermethylation of tumor suppressor genes (p16, APC, RUNX3, HPP1, TIMP3, etc. ) have been observed in the course of Barrett's esophageal carcinogenesis [4] . Because of this increased cancer risk, patients with BE traditionally undergo endoscopic surveillance at regular intervals, usually every two to three years if no additional abnormal findings are present [1] , [5] . Therefore, patients often undergo as many as ten or more surveillance endoscopies during a lifetime. In the United States, there are approximately 86.2 million whites between the ages of 45 and 80 years [6] . With a presumed BE prevalence rate of 1.6% [7] for whites, approximately 1.38 million of these subjects have BE. However, because the incidence of EAC in BE is uncommon (approximately 1/200 patient-years), most surveillance endoscopies in BE patients do not detect cancer. Therefore, Barrett's esophagus surveillance would benefit from effective markers to stratify patients according to their level of cancer progression risk. The currently accepted marker for cancer risk is histologic dysplasia, with high-grade dysplasia (HGD) being considered more accurate than low-grade dysplasia (LGD) [8] , [9] . In many centers, confirmed HGD is treated in the same manner as is early-stage EAC, by endoscopic mucosal ablation [10] , [11] , photodynamic therapy [10] , or surgical esophagectomy [12] . In contrast to HGD, the predictive value of LGD for cancer risk assessment is controversial [9] , [13] . Moreover, poor reproducibility (high inter-observer variation [8] , [14] ) in histologic assessment often makes clinical risk assessment problematic. Thus, more accurate tissue-based biomarkers capable of predicting the risk of progression to HGD or EAC would be highly useful. For the past several years, several groups have studied the role of DNA methylation in esophageal EAC development and progression [4] . Aberrant DNA methylation occurs early in this process, specifically in BE, and methylation increases in frequency in LGD and HGD, becoming most common in EAC [4] , [15] . We have shown that certain tumor suppressor genes that undergo methylation in BE can function as biomarkers, predicting whether BE patients will or will not develop HGD or EAC [15] . In actual clinical circumstances, it is difficult to develop prediction models exhibiting both high sensitivity and specificity. When the cutoff point of a prediction outcome is selected to maximize sensitivity, specificity will suffer, and false positives will increase. Conversely, if the cutoff point of a prediction outcome is chosen for high specificity, sensitivity will be lower. To solve this dilemma, we propose a 3-tiered stratification approach. With this method, patients are stratified into either high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. In the current manuscript, we demonstrate the prediction accuracy, statistical significance, and potential clinical impact of this three-tiered risk stratification system. MATERIALS AND METHODS HGD and EAC are not the same biological or clinical entity. Thus, combining them into a single neoplastic progression endpoint may appear nonstringent [15] . However, at the level of clinical utility, a pronounced shift in management strategy ( i.e., more intensive endoscopic surveillance and/or therapeutic intervention) occurs when HGD is diagnosed in BE [10] . For this reason, the progression endpoint was defined as either HGD or EAC. DEFINITION OF BARRETT'S ESOPHAGUS PROGRESSOR PATIENTS AND SPECIMENS Previously [15] , we defined BE progressor patients as BE subjects with either no dysplasia or LGD who later developed HGD or EAC, while progressor specimens were defined as any BE tissues obtained prior to the progression endpoint. However, in the clinical setting, it is important to know whether or not BE will progress prior to the next scheduled endoscopy. For this reason, in the current study, progressor specimens (P) were divided into 3 subgroups: P(0-2), P(2-4), and P(4-), defined as BE or LGD tissues obtained at 0–2 years, 2–4 years, or more than 4 years prior to the progression endpoint, respectively. Similarly, non-progressor specimens (NP) were defined as BE or LGD tissues obtained at 0–2 years [NP(0-2)], 2–4 years [NP(2-4)], or more than 4 years [P(4-)] before the non-progression follow-up date. PATIENTS AND TISSUES Patients undergoing endoscopy at the University of Maryland Medical Center, the Baltimore VA Hospital, and the Mayo Clinic provided written informed consent under a protocol approved by the Institutional Review Boards at each respective institution. Biopsies were taken using a standardized protocol.

Read the complete text